US stock · Healthcare sector · Biotechnology
Company Logo

Exelixis, Inc.

EXELNASDAQ

15.68

USD
-0.16
(-1.01%)
Market Closed
19.18P/E
15Forward P/E
0.96P/E to S&P500
5.046BMarket CAP
- -Div Yield
Upcoming Earnings
31 Oct-4 Nov
Shares Short
8/31/22
9.74M
Short % of Float
3.42%
Short % of Shares Outs.
3.03%
% Held by Insiders
2.16%
% Held by Institutions
89.91%
Beta
0.65
PEG Ratio
0.39
52w. high/low
23.40/15.50
Avg. Daily Volume
2.10M
Return %
Stock
S&P 500
1 year
(24.75)
(16.20)
3 years
(11.46)
22.35
5 years
(34.16)
44.82
Scale: |
High
Low
12.77
7.82
8.95
2.11
8.00
4.09
9.20
2.86
12.82
3.94
6.95
4.19
6.20
4.32
8.41
1.26
6.80
1.46
18.29
3.55
32.50
14.22
32.20
13.42
25.31
15.02
27.80
13.67
25.77
15.50
23.40
15.68
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.14
1.14
1.12
1.42
1.71
2.30
0.30
0.17
0.13
0.18
0.76
1.54
2.87
3.20
3.20
4.55
4.88
Earnings per share
(1.17)
(0.87)
(1.54)
(1.26)
(0.85)
0.60
(0.92)
(1.33)
(1.38)
(0.81)
(0.28)
0.53
2.32
1.06
0.36
0.73
0.85
FCF per share
(0.66)
(0.87)
(0.24)
(0.19)
(0.95)
(1.27)
(0.79)
(1.09)
(1.21)
(0.68)
0.82
0.49
1.28
1.70
0.58
1.07
0.97
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.13
0.18
0.14
0.06
0.02
0.01
0.02
0.01
0.00
0.00
0.01
0.07
0.11
0.04
0.10
0.20
0.15
Book Value per sh.
0.61
0.73
(0.54)
(1.53)
(2.10)
0.72
1.85
0.36
(0.59)
(0.50)
0.36
0.97
4.32
5.57
6.10
7.01
7.07
Comm.Shares outs.
87
99
105
107
109
126
160
184
194
209
251
294
298
303
308
315
318
Avg. annual P/E ratio
(8.5)
(12.0)
(3.6)
(4.4)
(6.2)
14.0
(5.6)
(3.8)
(2.7)
(5.2)
(31.1)
45.4
9.2
19.0
59.5
28.5
19.2
P/E to S&P500
(0.5)
(0.7)
(0.1)
(0.1)
(0.3)
0.9
(0.4)
(0.2)
(0.1)
(0.3)
(1.4)
1.9
0.4
0.8
1.6
0.9
1.0
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
99
113
118
152
185
290
47
31
25
37
191
452
854
968
988
1,435
1,555
Operating margin
(128.5)%
(138.4)%
(152.1)%
(80.3)%
(49.4)%
30.9%
(258.0)%
(640.5)%
(893.9)%
(326.6)%
(14.7)%
36.7%
51.4%
38.2%
11.1%
20.0%
21.2%
Depreciation (m)
17
11
13
13
11
7
6
3
2
1
1
1
8
8
9
14
16
Net profit (m)
(101)
(86)
(163)
(135)
(92)
76
(148)
(245)
(269)
(170)
(70)
154
690
321
112
231
273
Income tax rate
- -
- -
- -
0.9%
0.1%
1.7%
(0.1)%
0.0%
0.1%
(0.0)%
- -
2.7%
(52.6)%
19.4%
14.6%
21.4%
21.8%
Net profit margin
(102.9)%
(76.1)%
(138.2)%
(89.1)%
(49.9)%
26.1%
(311.2)%
(781.0)%
(1,069.4)%
(456.6)%
(36.7)%
34.1%
80.8%
33.2%
11.3%
16.1%
17.2%
Working capital (m)
151
151
82
23
(16)
136
351
179
(5)
126
200
370
792
868
1,241
1,497
1,547
Long-term debt (m)
108
106
75
40
171
177
323
335
262
381
- -
- -
12
48
49
51
161
Equity (m)
53
72
(57)
(164)
(228)
91
296
66
(115)
(104)
89
285
1,287
1,686
1,879
2,211
2,391
ROIC
- -
- -
- -
(90.0)%
(51.6)%
30.5%
(18.9)%
(48.0)%
(140.9)%
(43.2)%
(11.4)%
30.1%
52.4%
18.4%
5.8%
10.1%
10.5%
Return on capital
(25.7)%
(21.0)%
(40.5)%
(36.1)%
(23.0)%
23.7%
(16.7)%
(39.6)%
(67.1)%
(36.4)%
(6.2)%
25.5%
31.8%
21.1%
6.1%
11.2%
12.0%
Return on equity
(193.2)%
(119.8)%
285.8%
82.6%
40.4%
83.5%
(49.8)%
(369.5)%
233.9%
162.7%
(78.6)%
54.1%
53.6%
19.0%
5.9%
10.5%
11.4%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
113.0%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(5.1)%
Capital Structure
9 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 490
Total assets
$ 2,881
Long-term debt
$ 161
Cash and equiv.
$ 627
Goodwill
$ 64
Retained earnings
$ (77)
Common stock
321
Enterprise Value
$ 4,580
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
852
1,207
1,467
Receivables
119
161
283
Inventory
13
21
27
Other
27
110
438
Current assets
1,011
1,445
1,835
Acc. Payable
12
24
24
Debt due
3
- -
- -
Other
128
181
313
Current liabilities
143
205
338
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
45.31%
37.35%
77.22%
Cash flow
88.42%
55.58%
(1.54)%
Earnings
106.71%
83.87%
(0.45)%
Dividends
- -
- -
- -
Book value
17.64%
102.96%
9.45%
Insider Trading
Type
Shares
Date
Haley Patrick J.
Exempt
40,000
09/12/22
Haley Patrick J.
Sale
40,000
09/12/22
Haley Patrick J.
Exempt
40,000
09/12/22
Senner Christopher J.
Exempt
225,000
08/11/22
Senner Christopher J.
InKind
152,867
08/11/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
227
259
231
270
988
2021
270
385
328
451
1,435
2022
356
419
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.16
0.22
(0.10)
0.09
0.36
2021
0.01
0.30
0.12
0.30
0.73
2022
0.21
0.22
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Dr. Michael Morrissey
Full-time employees:
954
City:
Alameda
Address:
1851 Harbor Bay Pkwy
IPO:
Apr 11, 2000
Website:
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.